A rise in the global geriatric
population, increasing number of patients suffering from Parkinson’s
disease (PD) and growing awareness about neurological movement disorders
among patients have triggered the growth of the deep brain stimulation
devices market. Globally, neurological disorders are one of the major
causes of mortality and account for approximately 12% of deaths per
annum. Of these, cerebrovascular diseases account for 85% deaths.
Parkinson’s disease is the most common neurological disorder after
Alzheimer’s disease. Symptoms associated with this disease include
tremors, slowness of movement, muscle stiffness and trouble with
balance. Drug therapy is the most effective treatment option available
to control PD in the initial stages; however, a large number of
medicines are required to control the disease during its advanced
stages. In the later stages of PD, surgical treatment using deep brain
stimulation (DBS) devices is used to control symptoms of the disease.
DBS devices are an effective, clinically proven and legally approved
advanced treatment option for mild to severe PD. The market for DBS
devices is expected to grow at a significant rate during the forecast
period from 2014 to 2020. However, the high cost of the surgical
procedure could hamper the growth of the market. The growing burden of
PD on health care systems, along with the uncertainty of economic
conditions in some developed economies such as the U.S. and Europe has
forced original equipment manufacturers (OEMs) to develop cost-effective
devices for PD treatment.
This market research report on DBS
devices for the treatment of Parkinson’s disease provides detailed
analysis of the global market and helps in understanding the driving
forces responsible for the growth of the market. The report discusses
the market for deep brain stimulation devices for Parkinson’s disease
based on prevalence of the disease and the use of these devices to treat
PD in four geographical regions: North America, Europe, Asia Pacific
and Rest of the World. This report comprises an elaborate executive
summary, which includes a market snapshot that provides overall
information on various segments and sub-segments that are included in
the scope of the study. It also provides overall information and data
analysis of the global market for deep brain stimulation devices for
Parkinson’s disease with respect to market segments based on geography
(i.e., region-wise and country-wise analyses).
The global market for DBS devices for
Parkinson’s disease has been segmented with respect to geography. Market
size estimates and forecasts for the period from 2012 to 2020 have been
provided for each geographical region in terms of revenue (USD
million), considering 2012 and 2013 as historical and base years,
respectively. The CAGR (%) of each market segment for the forecast
period from 2014 to 2020 has also been provided along with market size
estimations. The market overview section provides a detailed qualitative
analysis of the factors responsible for driving and restraining the
growth of the global market for deep brain stimulation devices for the
treatment of Parkinson’s disease. The section also covers opportunities,
Porter’s five forces analysis as well as market attractiveness analysis
and market share analysis of major players in the global DBS devices
market.
A list of recommendations has been
provided for new entrants and existing market players to help them
establish a strong presence in the market and increase their share. The
report also profiles the major players in the market for deep brain
stimulation devices for Parkinson’s disease based on various attributes.
The profiles include company overview, financial overview, business
strategies, product portfolio and recent developments. Prominent players
profiled in the report include Medtronic, Inc., St. Jude Medical, Inc.,
Boston Scientific Corporation and Aleva Neurotherapeutics SA.
No comments:
Post a Comment